Sobi receives FDA clearance to manufacture Kineret in Austria
Kineret binds to the interleukin-1 type 1 receptor found in various tissues and organs and obstructs the biological activity of IL-1, which is a key mediator of inflammation
Ionis Pharmaceuticals has entered a licence agreement granting global pharmaceutical company Recordati exclusive rights to develop and commercialise zilganersen to treat Alexander disease (AxD) in countries outside the US.
The Protein Purification Facility will leverage the cGMP compatible stable, non-lytic protein expression platform for expression of complex and challenging proteins, including Fab fragments and other proteins. ExpreS2ion